Policy and Advocacy Library
The Policy and Advocacy Library is the culmination of the collaborative work of RACP members and comprises a comprehensive range of evidence-based, published RACP position statements, policies and submissions.
Can’t find what you’re looking for?
Please email email@example.com or use the online contact form.
How can I contribute my expertise?
RACP Trainees and Physicians need to see Represent Your Profession or email firstname.lastname@example.org or use the online contact form.
The Esther Foundation, which recently entered voluntary administration, was a Christian rehabilitation facility based in Perth which welcomed young women and teenagers to assist them through trauma and crisis situations including drug abuse and domestic violence.
This submission to the Parliament of Western Australia’s Inquiry into the Esther Foundation and unregulated private health facilities has been led by College’s Australasian Chapter of Addiction Medicine (AChAM) in consultation with relevant committees.
It outlines the principles which need to be followed by rehabilitation facilities which provide support for people with substance use disorder. It also makes the case for sustained, long-term funding to increase the capacity of drug and alcohol services to meet the demand for treatment, combined with real and persistent efforts to reduce disadvantage and inequities within society, as the only real solution to reducing substance dependence and related problems.
The RACP submission to the Independent Hospital Pricing Authority’s (IHPA) annual consultation on the Pricing Framework for Australian Public Hospital Services 2023-24 addresses impacts of COVID-19, classifications used to describe and price public hospital services, adjustments to the National Efficient Price and the National Efficient Cost and innovative funding models and service integration.
This submission provides the RACP’s feedback to inform the Australian National Audit Office’s (ANAO) audit of the Department of Health’s management of the expansion of telehealth services in response to the COVID-19 pandemic from March 2020 onwards, including the implementation of telehealth services as a permanent feature of Medicare.
The RACP welcomes the Ministry of Health’s proposal to extend the Schedule of the Specified Prescription Medicines for Designated Registered Nurse Prescribers 2016 to include oral antiviral medicines Paxlovid and Lageviro for the treatment of COVID-19. RACP members who provided feedback regarding this proposal were in unanimous support of the amendments to the Schedule. A key reason given for support of this proposal was to improve equitable and timely access to treatments among populations more vulnerable to the effects of COVID-19.
The RACP strongly supports the Ministry of Education’s proposed changes to the promotion and provision of healthy drinks in schools in Aotearoa New Zealand. Our preferred option is a healthy drinks policy in both primary and secondary schools. Effective implementation will depend on partnership with young people in decision making.
The Ministry of Health’s proposal to extend the schedule of the Medicines (Designated Pharmacist Prescribers) Regulations 2013 and include several medicines for the treatment of COVID-19 provides a useful new toolkit, with potential to prevent hospitalisation and death. However, there are divergent views on the inclusion of specific medicines on the schedule and risks to patients. We note the lack of commitment to equity of access to COVID therapeutics and equity of outcomes in addition to the schedule in this proposal, as well as the lack of specific detail about the new medicines.
The RACP strongly supports the proposal to include a warning and advisory statement relating to the harm of opioid abuse, misuse, and dependence on package labelling of opioid medicines. However, the RACP cautions that this statement will not be enough on its own to tackle opioid-related harm. A wide range of actions are needed to ensure an opioid crisis does not take hold in Aotearoa.
This submission outlines our support for the draft National Tobacco Strategy 2022-2030, the need for strong regulation of novel and emerging products with a focus on youth, as well as additional recommendations for international collaboration in tobacco control.